Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020:1257:155-168.
doi: 10.1007/978-3-030-43032-0_13.

Nanocapsule Delivery of IL-12

Justin E Markel  1 , Ryan A Lacinski  1 , Brock A Lindsey  2
Affiliations
Review

Nanocapsule Delivery of IL-12

Justin E Markel et al. Adv Exp Med Biol. 2020.

Abstract

Interleukin(IL)-12 is a protein that activates T cells and macrophages to kill tumor cells. However, despite this cytokine showing strong antitumor activity in preclinical settings, translation to patients has been slowed by toxic side effects, poor distribution to peripheral tissues, and improper dosing regimens. Osteosarcoma (OS) is an aggressive primary tumor of bone that has shown particular responsiveness to recombinant (r)IL-12 in preclinical models. Poly(lactic-co-glycolic) acid (PLGA) nanospheres, an FDA-approved drug delivery vector, may be a viable delivery vector for transporting biologically active IL-12 to tissues without disturbing normal homeostasis. In this chapter, we explore the potential for using IL-12-loaded nanospheres (IL-12-NS, <1 μm in diameter) to treat cancer, describe the synthesis process, and examine a typical protein release profile while providing insight and future directions of nanoscale tumor immunotherapeutics.

Keywords: IL-12; Immunotherapy; Nanocapsule; Nanoparticle; Osteosarcoma; PLGA.

PubMed Disclaimer

References

    1. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ et al (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153(4):1697–1706 - PubMed
    1. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M et al (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178(4):1223–1230 - PubMed
    1. Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13(1):251–276 - PubMed
    1. Cavallo F, Di Carlo E, Butera M, Verrua R, Colombo MP, Musiani P, Forni G (1999) Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res 59(2):414–421 - PubMed
    1. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, Romagnani S (1993) Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177(4):1199–1204 - PubMed

MeSH terms

LinkOut - more resources